You are here
Peer-reviewed articles on Melanoma related clinical trials
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With MelanomaTreated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB.J Clin Oncol. 2015 Aug 17.
Buchbinder EI, Sosman JA, Lawrence DP, McDermott DF, Ramaiya NH, Van den Abbeele AD, Linette GP, Giobbie-Hurder A, Hodi FS.Cancer. 2015 Aug 11. doi: 10.1002/cncr.29622
Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors
Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MM, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, Long GV.Cancer. 2015 Jul 28. doi: 10.1002/cncr.29586.
Swapnil D. Kachare, Patreek Singla, Nasreen A. Vohra, Emmanuel E. Zervos, Jan H. Wong, Timothy L. Fitzgerald
Surgery, Available online 19 June 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean-Jacques Grob, Vanna Chiarion-Sileni, Celeste Lebbe, Mario Mandala, Michael Millward, Ana Arance, Igor BoThe Lancet, Available online 31 May 2015
Michael A. Postow, M.D., Jason Chesney, M.D., Ph.D., Anna C. Pavlick, D.O., Caroline Robert, M.D. et al.Background In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with...
Editors’ comment: Dr. Paolo Ascierto
The CTLA-4 and PD-L1 pathways inhibit the antitumor immunity with two different and complementary mechanisms. For this reason in the last few years emerged the conviction that the combination of two different checkpoint inhibitors could lead to an higher improvement in terms of response and survival in patients with advanced melanoma. A previous phase I study showed an high response rates and a 2 years survival rate of 79% for patients treated with the combination of ipilimumab and nivolumab. In this Phase II study, 179 patients were randomized to receive the combination of ipilimumab and nivolumab vs ipilimumab alone. The study’s results confirmed the superiority of the combination in terms of effectiveness, showing an increase in ORR and PFS in all subgroups of patients, regardless of the BRAF mutational status and of the PD-L1 expression
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma
Dirk Schadendorf, Mayur M. Amonkar, Daniil Stroyakovskiy, Evgeny Levchenko, Helen Gogas, Filippo de Braud, Jean-Jacques Grob, Igor Bondarenko, Claus Garbe, Celeste Lebbe, James Larkin, Vanna Chiarion-Sileni, Michael Millward, Ana Arance, Mario Mandalà, Keith T. Flaherty, Paul Nathan, Antoni Ribas, Caroline Robert, Michelle Casey, Douglas J. DeMarini, Jhangir G. Irani, Gursel Aktan, Georgina V. Long
European Journal of Cancer, 7, 51, pages 833 - 840, Article in Press
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Dr Jeffrey S Weber, MDa, , , Sandra P D'Angelo, MDb, David Minor, MDc, F Stephen Hodi, MDd, Ralf Gutzmer, MDe, Bart Neyns, MDf, et al.Article in Press Summary Background Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can result in durable responses...
Prospective evaluation of follow-up in melanoma patients in Germany – Results of a multicentre and longitudinal study
E. Livingstone, C. Krajewski, T.K. Eigentler, C. Windemuth-Kieselbach, S. Benson, S. Elsenbruch, A. Hauschild, R. Rompel, F. Meiss, A. Mauerer, K.C. Kähler, E. Dippel, K. Möllenhoff, K. Kilian, P. Mohr, J. Utikal, D. Schadendorf
European Journal of Cancer